28487075|t|N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1δ / ε inhibitors: Synthesis, biological evaluation and molecular modeling studies
28487075|a|Described herein is the design, synthesis and biological evaluation of a series of N-(1H-pyrazol-3-yl)quinazolin-4-amines against a panel of eight disease relevant protein kinases. The kinase inhibition results indicated that two compounds inhibited casein kinase 1δ / ε (CK1δ / ε) with some selectivity over related kinases, namely CDK5/p25, GSK-3α / β, and DYRK1A. Docking studies with 3c and 3d revealed the key interactions with desired amino acids in the ATP binding site of CK1δ. Furthermore, compound 3c also elicited selective cytotoxic activity against the pancreas ductal adenocarcinoma (PANC-1) cell line. Taken together, the results of this study establish N-(1H-pyrazol-3-yl)quinazolin-4-amines especially 3c and 3d as valuable lead molecules with great potential for CK1δ / ε inhibitor development targeting neurodegenerative disorders and cancer.
28487075	0	38	N-(1H-Pyrazol-3-yl)quinazolin-4-amines	T121	C1254351
28487075	44	55	novel class	T080	C0205314
28487075	59	75	casein kinase 1δ	T116,T126	C1171766
28487075	78	79	ε	T116,T126	C0752519
28487075	80	90	inhibitors	T120	C0243077
28487075	92	101	Synthesis	T052	C1883254
28487075	103	113	biological	T080	C0205460
28487075	114	124	evaluation	T078	C1550157
28487075	129	155	molecular modeling studies	T062,T170	C0600115
28487075	180	186	design	T052	C1707689
28487075	188	197	synthesis	T052	C1883254
28487075	202	212	biological	T080	C0205460
28487075	213	223	evaluation	T078	C1550157
28487075	239	277	N-(1H-pyrazol-3-yl)quinazolin-4-amines	T121	C1254351
28487075	303	310	disease	T047	C0012634
28487075	311	319	relevant	T080	C2347946
28487075	320	335	protein kinases	T116,T126	C0033640
28487075	341	358	kinase inhibition	T044	C2247121
28487075	367	376	indicated	T033	C1444656
28487075	386	395	compounds	T121	C1254351
28487075	396	405	inhibited	T080	C0311403
28487075	406	422	casein kinase 1δ	T116,T126	C1171766
28487075	425	426	ε	T116,T126	C0752519
28487075	428	432	CK1δ	T116,T126	C1171766
28487075	435	436	ε	T116,T126	C0752519
28487075	448	459	selectivity	T080	C0205556
28487075	473	480	kinases	T116,T126	C0033640
28487075	489	497	CDK5/p25	T116,T126	C0249586
28487075	499	505	GSK-3α	T116,T126	C3853562
28487075	508	509	β	T116,T126	C4283740
28487075	515	521	DYRK1A	T116,T126	C1453762
28487075	523	530	Docking	T044	C1522290
28487075	531	538	studies	T059	C0947630
28487075	544	546	3c	T121	C1254351
28487075	551	553	3d	T121	C1254351
28487075	554	562	revealed	T080	C0443289
28487075	571	583	interactions	T169	C1704675
28487075	597	608	amino acids	T116,T121,T123	C0002520
28487075	616	619	ATP	T114,T121,T123	C0001480
28487075	620	632	binding site	T044	C1149343
28487075	636	640	CK1δ	T116,T126	C1171766
28487075	655	666	compound 3c	T121	C1254351
28487075	672	680	elicited	T080	C0449265
28487075	691	700	cytotoxic	T169	C1511636
28487075	701	709	activity	T052	C0441655
28487075	710	717	against	T080	C0521124
28487075	722	752	pancreas ductal adenocarcinoma	T191	C1335302
28487075	754	760	PANC-1	T191	C1335302
28487075	762	771	cell line	T025	C0085983
28487075	793	800	results	T169	C1274040
28487075	809	814	study	T062	C2603343
28487075	825	863	N-(1H-pyrazol-3-yl)quinazolin-4-amines	T121	C1254351
28487075	875	877	3c	T121	C1254351
28487075	882	884	3d	T121	C1254351
28487075	897	911	lead molecules	T167	C0567416
28487075	923	932	potential	T080	C3245505
28487075	937	941	CK1δ	T116,T126	C1171766
28487075	944	945	ε	T116,T126	C0752519
28487075	946	955	inhibitor	T120	C0243077
28487075	956	967	development	T169	C1527148
28487075	968	977	targeting	T169	C1521840
28487075	978	1005	neurodegenerative disorders	T047	C0524851
28487075	1010	1016	cancer	T191	C0006826